 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | Glycovax-002 / Glycovax Pharma
Trial completion date, Trial primary completion date: Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults (clinicaltrials.gov) - Sep 24, 2024
P1, N=36, Active, not recruiting, Sponsor: Glycovax Pharma Inc.
Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Jun 2024
- || Glycovax-002 / Glycovax Pharma
Enrollment closed, Trial primary completion date: Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults (clinicaltrials.gov) - Mar 21, 2024
P1, N=36, Active, not recruiting, Sponsor: Glycovax Pharma Inc.
Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Jun 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2023 --> Apr 2024
- || Glycovax-002 / Glycovax Pharma
Enrollment open: Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults (clinicaltrials.gov) - May 3, 2023
P1, N=36, Recruiting, Sponsor: Glycovax Pharma Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2023 --> Apr 2024 Not yet recruiting --> Recruiting
- || Glycovax-002 / Glycovax Pharma
New P1 trial: Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults (clinicaltrials.gov) - Apr 5, 2023
P1, N=36, Not yet recruiting, Sponsor: Glycovax Pharma Inc.